{"product_id":"understanding-thyroid-nodules-a-complete-guide-to-diagnosis-and-management","title":"Understanding Thyroid Nodules: A Complete Guide to Diagnosis and Management","description":"\u003cp\u003eThyroid nodules are growths in the butterfly-shaped thyroid gland that affect an estimated 20% to 60% of adults, yet fewer than 5% turn out to be cancerous. Modern evaluation combines blood tests, ultrasound imaging, and when needed, fine-needle aspiration biopsy. New ultrasound risk-stratification systems and molecular tests of biopsy samples have dramatically reduced the number of unnecessary biopsies and surgeries. Most thyroid nodules can be safely monitored over time, and treatment options—including surgery and newer nonsurgical ablation techniques—should be individualized for each patient.\u003c\/p\u003e\n\n\u003ch1\u003eUnderstanding Thyroid Nodules: A Complete Guide to Diagnosis and Management\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How the Evidence Was Gathered\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ultrasound\"\u003eUltrasound: The Gold Standard for Imaging\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ct-mri-pet\"\u003eThe Role of CT, MRI, and PET\/CT Scans\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#scintigraphy\"\u003eNuclear Thyroid Scans (Scintigraphy)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#fna-biopsy\"\u003eFine-Needle Aspiration Biopsy (FNAB)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#molecular-testing\"\u003eMolecular Testing: A Genetic Look at Nodules\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#management\"\u003eManagement and Follow-Up\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#surgery\"\u003eSurgical Treatment Options\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#nonsurgical\"\u003eNonsurgical Treatment Options\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#conclusion\"\u003eConclusion: Key Takeaways\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eMost thyroid nodules are benign; fewer than 5% are cancerous in the general population.\u003c\/li\u003e\n\u003cli\u003eUltrasound risk-stratification systems guide biopsy decisions, often avoiding biopsy for nodules under 1 centimeter.\u003c\/li\u003e\n\u003cli\u003eMolecular testing of indeterminate biopsy samples can reduce unnecessary diagnostic surgeries.\u003c\/li\u003e\n\u003cli\u003eActive surveillance is a recommended option for papillary microcarcinoma, a thyroid cancer smaller than 1 centimeter.\u003c\/li\u003e\n\u003cli\u003eNonsurgical treatments like ethanol ablation and thermal ablation are alternatives for benign symptomatic nodules.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eThyroid nodules (TN) are one of the most common reasons for an endocrinology consultation. Studies show they are present in 20% to 60% of people when healthy volunteers are randomly selected and screened with ultrasound. Most thyroid nodules cause no symptoms at all and are found by accident when a patient undergoes imaging—such as a CT scan, MRI, or ultrasound—for an unrelated reason. This is why they are often called \"incidentalomas.\"\u003c\/p\u003e\n\n\u003cp\u003eAlthough the number of thyroid cancer cases has risen in recent decades, the vast majority of thyroid nodules are \u003cstrong\u003ebenign\u003c\/strong\u003e (non-cancerous). The rate of malignancy is less than 5% in the general population, though the abstract of this paper cites a 7%–15% risk range based on broader pooled data. That distinction matters: doctors need to determine which nodules deserve closer attention and which can simply be left alone.\u003c\/p\u003e\n\n\u003cp\u003eWhen a new thyroid nodule is discovered, the physician's goals are twofold: first, to determine whether it is benign or malignant (cancerous), and second, for symptomatic benign nodules, to establish whether treatment is needed to relieve pressure-related symptoms. The authors of this review article emphasize that \u003cstrong\u003eroutine population screening for thyroid nodules is not recommended\u003c\/strong\u003e. However, they stress that extra attention should be paid to people with known risk factors for thyroid cancer.\u003c\/p\u003e\n\n\u003cp\u003eThose risk factors include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA history of exposure to ionizing radiation during childhood\u003c\/li\u003e\n  \u003cli\u003eVariations in dietary iodine intake (both low and high iodine can affect thyroid health)\u003c\/li\u003e\n  \u003cli\u003eInherited genetic syndromes linked to thyroid cancer, including \u003cstrong\u003efamilial adenomatous polyposis\u003c\/strong\u003e, \u003cstrong\u003eCarney complex\u003c\/strong\u003e, \u003cstrong\u003eCowden syndrome\u003c\/strong\u003e, \u003cstrong\u003ePTEN hamartoma tumor syndrome\u003c\/strong\u003e, and \u003cstrong\u003ePeutz-Jeghers syndrome\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eA family history of \u003cstrong\u003emedullary thyroid cancer\u003c\/strong\u003e or \u003cstrong\u003emultiple endocrine neoplasia (MEN) syndrome\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How the Evidence Was Gathered\u003c\/h2\u003e\n\n\u003cp\u003eThis article is a \u003cstrong\u003ecomprehensive literature review\u003c\/strong\u003e, not a single clinical trial. The authors—Dr. Victor J. Bernet and Dr. Ana-Maria Chindris from the Division of Endocrinology at the Mayo Clinic in Florida—conducted a systematic search of two major medical databases, PubMed and Medline, looking for articles published in the past 5 years that focused on the epidemiology, diagnosis, and management of thyroid nodules.\u003c\/p\u003e\n\n\u003cp\u003eThe search identified \u003cstrong\u003e135 relevant articles\u003c\/strong\u003e, which the authors reviewed in depth. They also examined the reference lists of those articles to find additional pertinent studies, ensuring the review captured both the latest evidence and important older foundational studies.\u003c\/p\u003e\n\n\u003ch2 id=\"ultrasound\"\u003eUltrasound: The Gold Standard for Imaging\u003c\/h2\u003e\n\n\u003cp\u003eThyroid ultrasound (US) is the single most important imaging test for evaluating thyroid nodules. It is considered the \u003cstrong\u003egold standard\u003c\/strong\u003e for assessing nodule shape, size, and internal characteristics. Ultrasound is generally recommended for any nodule discovered either by physical examination or through other imaging tests, such as CT or MRI. Thanks to significant technological improvements, modern ultrasound can provide a remarkably detailed picture of thyroid anatomy.\u003c\/p\u003e\n\n\u003cp\u003eSeveral ultrasound features have been linked to an increased risk of thyroid cancer. These include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSize\u003c\/strong\u003e of the nodule\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEchogenicity\u003c\/strong\u003e—whether the nodule appears darker (hypoechoic) or brighter (hyperechoic) than the surrounding thyroid tissue\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNodule borders\u003c\/strong\u003e—irregular or lobulated edges are more concerning\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVascular pattern\u003c\/strong\u003e—increased blood flow inside the nodule (a type III vascular pattern)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eShape\u003c\/strong\u003e—nodules that are \"taller than wide\" on a transverse (cross-sectional) view are suspicious\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTissue stiffness\u003c\/strong\u003e, measured by a technique called \u003cstrong\u003eelastography\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eThe presence of \u003cstrong\u003emicrocalcifications\u003c\/strong\u003e (tiny calcium deposits) or \u003cstrong\u003emacrocalcifications\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eAbnormally appearing \u003cstrong\u003ecervical lymph nodes\u003c\/strong\u003e in the neck\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eHowever, the authors caution that no single ultrasound feature is accurate enough to diagnose cancer on its own. Each feature has a broad range of sensitivity and specificity, meaning some cancers show none of these signs, and many benign nodules show several of them. For this reason, doctors now use \u003cstrong\u003erisk-stratification systems\u003c\/strong\u003e that combine multiple features to estimate the probability of malignancy and guide whether a biopsy is needed.\u003c\/p\u003e\n\n\u003ch3\u003eTI-RADS: The American College of Radiology System\u003c\/h3\u003e\n\n\u003cp\u003eIn 2017, the American College of Radiology (ACR) published a standardized scoring system called \u003cstrong\u003eTI-RADS\u003c\/strong\u003e (Thyroid Imaging, Reporting and Data System). This system assigns points based on five categories: nodule composition (solid vs. cystic), echogenicity, shape, margins, and the presence of echogenic foci (calcifications). The total score determines the TI-RADS level, and the recommendation for \u003cstrong\u003efine-needle aspiration biopsy (FNAB)\u003c\/strong\u003e is based on a combination of the TI-RADS score and nodule size.\u003c\/p\u003e\n\n\u003ch3\u003eThe American Thyroid Association (ATA) System\u003c\/h3\u003e\n\n\u003cp\u003eThe ATA system takes a different approach. Instead of point scoring, it relies on \u003cstrong\u003esonographic pattern recognition\u003c\/strong\u003e, classifying nodules into 5 categories based on their overall appearance. Each category has an associated range of cancer risk:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBenign:\u003c\/strong\u003e less than 1% cancer risk\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eVery low suspicion:\u003c\/strong\u003e less than 3% cancer risk\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLow suspicion:\u003c\/strong\u003e 5%–10% cancer risk\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIntermediate suspicion:\u003c\/strong\u003e 10%–20% cancer risk\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHigh suspicion:\u003c\/strong\u003e more than 70%–90% cancer risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAs with TI-RADS, the ATA system uses nodule size combined with appearance to recommend when a biopsy should be performed. Importantly, \u003cstrong\u003eboth systems recommend against automatically biopsying nodules smaller than 1 centimeter\u003c\/strong\u003e, even when they look suspicious. Instead, they favor active surveillance with close follow-up for these small nodules, a departure from older practices.\u003c\/p\u003e\n\n\u003cp\u003eSimilar scoring systems have been developed by other professional societies around the world, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThe \u003cstrong\u003eKorean Society of Thyroid Radiology\u003c\/strong\u003e (K-TIRADS)\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003eEuropean Thyroid Association\u003c\/strong\u003e (EU-TIRADS)\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003eAmerican Association of Clinical Endocrinologists\u003c\/strong\u003e (AACE\/ACE\/AME)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe recommended biopsy size thresholds vary slightly between systems. For example, in the ACR TI-RADS system, a moderately suspicious (TI-RADS 4) nodule generally needs to reach 1.5 cm before biopsy is recommended, while a highly suspicious (TI-RADS 5) nodule warrants biopsy at 1.0 cm. In the ATA system, low-suspicion nodules need to be at least 2 cm for consideration of FNA, intermediate-suspicion nodules at 1.5 cm, and high-suspicion nodules at 1.0 cm. The European Thyroid Association's EU-TIRADS system recommends FNA at 2 cm for low-risk nodules (EU-TIRADS 3), 1.5 cm for intermediate-risk (EU-TIRADS 4), and 1.0 cm for high-risk (EU-TIRADS 5).\u003c\/p\u003e\n\n\u003ch2 id=\"ct-mri-pet\"\u003eThe Role of CT, MRI, and PET\/CT Scans\u003c\/h2\u003e\n\n\u003cp\u003eCT (computed tomography) and MRI (magnetic resonance imaging) have only \u003cstrong\u003elimited roles\u003c\/strong\u003e in the routine evaluation of thyroid nodules. They are generally reserved for specific situations, such as:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePatients with signs of advanced thyroid malignancy\u003c\/li\u003e\n  \u003cli\u003ePre-surgical planning for thyroid cancer\u003c\/li\u003e\n  \u003cli\u003eAssessment of lymph nodes in the central and lateral neck compartments\u003c\/li\u003e\n  \u003cli\u003eEvaluation of involvement of nearby structures, including the airway, digestive tract, or blood vessels\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003e18F-FDG PET\/CT\u003c\/strong\u003e scans — a type of imaging that measures metabolic activity — sometimes reveal thyroid nodules that were not previously known. The prevalence of such incidentally discovered thyroid nodules is \u003cstrong\u003e1%–2% of all 18F-FDG PET\/CT scans\u003c\/strong\u003e. When a nodule shows increased FDG uptake (meaning it is metabolically active), the reported rate of cytology-proven malignancy ranges from \u003cstrong\u003e24% to 58.2%\u003c\/strong\u003e. By contrast, \u003cstrong\u003ediffuse\u003c\/strong\u003e (widespread) uptake throughout the thyroid is associated with a much lower malignancy rate of just \u003cstrong\u003e4.4%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eA meta-analysis of 18 studies (with a total of 55,160 patients) found that \u003cstrong\u003e1% of patients\u003c\/strong\u003e had thyroid incidentalomas detected on FDG PET scans, with a \u003cstrong\u003e33.2% incidence of malignancy\u003c\/strong\u003e. Among those cancers, \u003cstrong\u003epapillary thyroid cancer made up 82.2%\u003c\/strong\u003e of cases.\u003c\/p\u003e\n\n\u003cp\u003eDespite this concerning rate, the authors point out that newly discovered incidental thyroid cancers on PET\/CT do not appear to affect overall survival. In a retrospective review of \u003cstrong\u003e45,000 PET\/CT scans\u003c\/strong\u003e, the incidence of thyroid cancer among thyroid incidentalomas was \u003cstrong\u003e36%\u003c\/strong\u003e. Over a median follow-up of \u003cstrong\u003e24 months\u003c\/strong\u003e, most of the 181 deaths that occurred were related to the patient's primary (original) malignancy — not the thyroid cancer.\u003c\/p\u003e\n\n\u003ch2 id=\"scintigraphy\"\u003eNuclear Thyroid Scans (Scintigraphy)\u003c\/h2\u003e\n\n\u003cp\u003eWhen a newly diagnosed thyroid nodule is accompanied by a \u003cstrong\u003esubnormal TSH level\u003c\/strong\u003e (a blood test that indicates the thyroid may be overactive), the next step should be a \u003cstrong\u003eradioactive iodine uptake test and thyroid scan\u003c\/strong\u003e to determine whether the nodule is \"hyperfunctioning\" (producing excess thyroid hormone on its own). In this setting, ultrasound can also be used to look for coexistent non-functioning nodules that might require additional evaluation.\u003c\/p\u003e\n\n\u003cp\u003eOne practical tip from the authors: small hyperfunctioning nodules may not fully suppress TSH. So if TSH is in the \u003cstrong\u003elower end of the normal range\u003c\/strong\u003e and there is clinical suspicion, scintigraphy should still be considered.\u003c\/p\u003e\n\n\u003cp\u003eHistorically, thyroid scintigraphy using \u003cstrong\u003e99mTc-pertechnetate\u003c\/strong\u003e and radioactive iodine (\u003cstrong\u003e131I\u003c\/strong\u003e and \u003cstrong\u003e123I\u003c\/strong\u003e) played a major role in evaluating thyroid nodules and multinodular goiters. In the United States today, nuclear thyroid imaging is \u003cstrong\u003eprimarily reserved for cases where TSH suppression is evident\u003c\/strong\u003e and thyrotoxicosis (overactive thyroid) is suspected. In Europe and other parts of the world, scintigraphy is used more commonly.\u003c\/p\u003e\n\n\u003cp\u003eThe key principle is simple: \u003cstrong\u003e\"cold\" nodules\u003c\/strong\u003e (those that do not take up radioactive material) can represent cancer, but many benign nodules also appear cold. \u003cstrong\u003e\"Hot\" or hyperfunctioning nodules\u003c\/strong\u003e (those that take up excess radioactive material) are \u003cstrong\u003erarely malignant\u003c\/strong\u003e — so a hot nodule generally does not require a biopsy.\u003c\/p\u003e\n\n\u003cp\u003eThe authors cite an older but important review from 1981, which examined 6 articles and found the following cancer rates based on scintigraphy results:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHypofunctioning (cold) nodules:\u003c\/strong\u003e 16% cancer rate\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNormofunctioning nodules:\u003c\/strong\u003e 29% cancer rate\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHyperfunctioning (hot) nodules:\u003c\/strong\u003e 24% cancer rate\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eInterestingly, discrepancies have been reported between how nodules take up 99mTc versus 131I, particularly in \u003cstrong\u003efollicular thyroid cancer\u003c\/strong\u003e. Some nodules showed uptake on 99mTc imaging but appeared \"cold\" on 131I imaging. For this reason, when scintigraphy is used, \u003cstrong\u003e123I is preferred over 99mTc\u003c\/strong\u003e as the imaging agent.\u003c\/p\u003e\n\n\u003cp\u003eA recent study comparing 123I scintigraphy and thyroid ultrasound for guiding biopsy decisions found \u003cstrong\u003econcordant recommendations in 79.4% of cases\u003c\/strong\u003e. Among the discordant cases, ultrasound recommended FNA for functional (hot) nodules in \u003cstrong\u003e3.8%\u003c\/strong\u003e of cases, while 123I scintigraphy recommended FNA in \u003cstrong\u003e7.9%\u003c\/strong\u003e of cases where either no nodule was seen on ultrasound or the nodule did not meet ultrasound-guided FNA criteria.\u003c\/p\u003e\n\n\u003cp\u003eThe 2015 American Thyroid Association guidelines recommend \u003cstrong\u003elimited use of thyroid scintigraphy\u003c\/strong\u003e, primarily for patients with suppressed TSH. The rationale is that identifying an autonomous (self-functioning) nodule would eliminate the need for FNA biopsy of that nodule — except in the rare cases where ultrasound appearance suggests malignancy. The European Association for Nuclear Medicine and the Society of Nuclear Medicine and Molecular Imaging have jointly published guidelines noting additional potential uses for scintigraphy, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eEvaluation of a multinodular goiter to identify a hyperfunctioning \"hot\" nodule that does not need FNA\u003c\/li\u003e\n  \u003cli\u003eEvaluation of suspicious hypofunctioning \"cold\" areas within a multinodular goiter that may need FNA\u003c\/li\u003e\n  \u003cli\u003eEvaluation of nodules with indeterminate FNA cytology, to identify autonomous functioning nodules\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eTSH suppression from autonomous nodules can vary based on local dietary iodine intake. In populations with lower dietary iodine intake, autonomous nodules with low-reference-range TSH levels are more common. Scintigraphy has also been proposed as a way to identify autonomous nodules early, allowing close follow-up to detect the possible future development of full-blown thyrotoxicosis.\u003c\/p\u003e\n\n\u003cp\u003eThe bottom line: while most patients with normal thyroid function (euthyroid) do not need scintigraphy, local factors may influence the decision to use this imaging tool.\u003c\/p\u003e\n\n\u003ch2 id=\"fna-biopsy\"\u003eFine-Needle Aspiration Biopsy (FNAB)\u003c\/h2\u003e\n\n\u003cp\u003eWhen a thyroid nodule meets the morphologic criteria on ultrasound (based on risk-stratification systems), it should be further assessed by \u003cstrong\u003efine-needle aspiration biopsy (FNAB)\u003c\/strong\u003e. This is the standard method for determining whether a nodule is benign or malignant.\u003c\/p\u003e\n\n\u003cp\u003eFNAB is a \u003cstrong\u003estraightforward outpatient procedure\u003c\/strong\u003e performed under ultrasound guidance. It typically uses \u003cstrong\u003e27-gauge and 25-gauge sterile needles\u003c\/strong\u003e — very thin needles, similar to those used for routine blood draws. Local anesthesia is sometimes used, although its benefit in reducing discomfort with such fine needles has been challenged in the literature. Complications are uncommon and are generally limited to local bruising and, rarely, a hematoma (a collection of blood under the skin).\u003c\/p\u003e\n\n\u003cp\u003eStudies examining the relationship between nodule size and FNAB accuracy have produced conflicting results. For nodules smaller than 1 centimeter, FNAB accuracy ranged from \u003cstrong\u003e60% to 94%\u003c\/strong\u003e. For nodules larger than 4 centimeters, accuracy ranged from \u003cstrong\u003e80.3% to 87.5%\u003c\/strong\u003e. Interestingly, very large nodules are not always easier to sample accurately, because they may contain areas of degeneration or cystic fluid that dilute the cellular sample.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCore needle biopsy\u003c\/strong\u003e (which uses a slightly larger needle to obtain a small tissue core) is currently considered when:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eFNAB yields nondiagnostic results (not enough cells to interpret), or\u003c\/li\u003e\n  \u003cli\u003eThyroid lymphoma or anaplastic thyroid cancer is suspected\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe Korean Society of Thyroid Radiology goes further, recommending core needle biopsy as a \u003cstrong\u003efirst-line alternative\u003c\/strong\u003e to FNAB. However, core needle biopsy carries a higher rate of complications, including post-biopsy hematomas, bleeding from the incision site, pain, infections, transient coughing up of blood (hemoptysis), and nerve injuries.\u003c\/p\u003e\n\n\u003ch3\u003eThe Bethesda System for Reporting Cytology\u003c\/h3\u003e\n\n\u003cp\u003eCytology results from FNAB are classified according to the \u003cstrong\u003eBethesda criteria\u003c\/strong\u003e, which divide nodules into \u003cstrong\u003e6 categories\u003c\/strong\u003e. Each category has an associated malignancy risk and corresponding management recommendation. The two categories that create the most clinical uncertainty are:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBethesda III\u003c\/strong\u003e (atypia of undetermined significance): 10%–30% malignancy risk\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBethesda IV\u003c\/strong\u003e (follicular neoplasm or suspicious for follicular neoplasm): 25%–40% malignancy risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThese are known as \u003cstrong\u003eindeterminate cytology\u003c\/strong\u003e results. Historically, the only way to get a definitive diagnosis in these cases was to perform surgery to remove the nodule. Not surprisingly, this led to a \u003cstrong\u003esignificant number of unnecessary surgeries\u003c\/strong\u003e, because many of these nodules ultimately turned out to be benign.\u003c\/p\u003e\n\n\u003ch2 id=\"molecular-testing\"\u003eMolecular Testing: A Genetic Look at Nodules\u003c\/h2\u003e\n\n\u003cp\u003eIn recent years, a major advance has been the introduction of \u003cstrong\u003emolecular testing\u003c\/strong\u003e of cytology samples from indeterminate nodules. These tests look for genomic alterations associated with thyroid malignancy—including gene mutations, gene fusions, and differences in RNA and microRNA expression—that are linked to a higher risk of cancer.\u003c\/p\u003e\n\n\u003cp\u003eThe most prevalent commercially available molecular tests for thyroid nodule malignancy assessment include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAfirma Genomic Sequencing Classifier\u003c\/strong\u003e with add-on Xpression Atlas (Veracyte)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThyroSeq 3.0\u003c\/strong\u003e (Sonic Healthcare USA Thyroseq Laboratory)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThyGenX\/ThyraMIR\u003c\/strong\u003e (Thyramir Interpace Diagnostics)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRosetta GX Reveal\u003c\/strong\u003e (Rosetta Genomics)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMutations identified by these tests can also help guide management. For example, the simultaneous presence of \u003cstrong\u003eBRAF V600E\u003c\/strong\u003e and \u003cstrong\u003eTERT C228T\u003c\/strong\u003e mutations in papillary thyroid cancer is associated with poorer outcomes, so this finding may have both prognostic value and implications for management decisions. Conversely, the \u003cstrong\u003eRAS mutation\u003c\/strong\u003e has been identified in a wide spectrum of conditions—from benign nodules and follicular adenomas to noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), classic and follicular variant papillary thyroid cancer, poorly differentiated thyroid cancer, and even anaplastic and medullary thyroid cancers. This broad range means RAS mutations alone do not definitively diagnose cancer.\u003c\/p\u003e\n\n\u003cp\u003eThe authors temper this enthusiasm with an important caveat: \u003cstrong\u003eusing molecular marker results to guide therapeutic recommendations\u003c\/strong\u003e (such as the extent of surgery or whether to give radioactive iodine) has \u003cstrong\u003enot yet been proven to improve outcomes\u003c\/strong\u003e and is \u003cstrong\u003enot yet considered the standard of care\u003c\/strong\u003e. In addition, the relatively high cost of these tests may be a limiting factor for many patients.\u003c\/p\u003e\n\n\u003ch2 id=\"management\"\u003eManagement and Follow-Up\u003c\/h2\u003e\n\n\u003cp\u003eOnce a thyroid nodule has been evaluated, the management plan depends heavily on the biopsy results and ultrasound characteristics. There is no single unanimous consensus on every scenario, but several general principles guide clinical practice.\u003c\/p\u003e\n\n\u003ch3\u003eBenign Nodules\u003c\/h3\u003e\n\n\u003cp\u003eFor nodules with \u003cstrong\u003ebenign cytology (Bethesda II)\u003c\/strong\u003e that are asymptomatic, routine follow-up is recommended. The follow-up strategy—including the frequency of repeat ultrasound—should be based on \u003cstrong\u003eultrasound characteristics rather than simply on an increase in volume\u003c\/strong\u003e. The chance of cancer being found later in a nodule with benign cytology is low, and it \u003cstrong\u003eessentially becomes zero\u003c\/strong\u003e if a second sampling also yields benign cytology. Current guidelines recommend repeating FNA when concerning ultrasound characteristics develop or when the nodule grows by \u003cstrong\u003eat least 50% in volume\u003c\/strong\u003e—though the authors note that this growth criterion alone has been shown to have low specificity for malignancy.\u003c\/p\u003e\n\n\u003cp\u003eThere is ongoing debate about surveillance of \u003cstrong\u003esubcentimeter nodules\u003c\/strong\u003e (smaller than 1 cm). Highly suspicious subcentimeter nodules warrant repeat ultrasound at \u003cstrong\u003e6–12 months\u003c\/strong\u003e. On the other end of the spectrum, nodules with \u003cstrong\u003every low suspicion\u003c\/strong\u003e, regardless of size, do not require follow-up imaging at all. The American College of Radiology recommends against scanning intervals of \u003cstrong\u003eless than 1 year\u003c\/strong\u003e, except for biopsy-proven cancers under active surveillance.\u003c\/p\u003e\n\n\u003ch3\u003eNondiagnostic Cytology\u003c\/h3\u003e\n\n\u003cp\u003eNodules with nondiagnostic cytology should undergo a \u003cstrong\u003erepeat biopsy about 4–6 weeks later\u003c\/strong\u003e. Alternatively, core needle biopsy can be considered, especially if concerning ultrasound features are present.\u003c\/p\u003e\n\n\u003ch3\u003eThe Challenging \"High-Risk\" Small Nodule\u003c\/h3\u003e\n\n\u003cp\u003eNodules that are below the size threshold for FNAB but have \"high-risk\" ultrasound features represent a challenging category. Most guidelines recommend monitoring these high-risk subcentimeter nodules with repeat ultrasound every \u003cstrong\u003e6–12 months\u003c\/strong\u003e, unless additional risk factors are present. However, in clinical practice, many patients prefer not to wait, and they push for FNAB despite the small size.\u003c\/p\u003e\n\n\u003cp\u003eThis is understandable, but sample adequacy is a real concern. For tiny nodules, getting enough cells to interpret can be difficult:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eAdequacy rates are reported to be as low as \u003cstrong\u003e72.2% for nodules 3–6 mm\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003e84.9% for nodules 7–10 mm\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003eAnd only \u003cstrong\u003e63% in the presence of macrocalcifications\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eWhy TSH Suppression Therapy Fell Out of Favor\u003c\/h3\u003e\n\n\u003cp\u003eFor many years, doctors treated benign thyroid nodules with \u003cstrong\u003ethyroid hormone (levothyroxine) suppression therapy\u003c\/strong\u003e, aiming to shrink nodules by keeping TSH levels low. A meta-analysis published in 2005 found an \u003cstrong\u003e88% likelihood of achieving a reduction in nodule volume of greater than 50%\u003c\/strong\u003e compared with placebo or no treatment. That sounds impressive.\u003c\/p\u003e\n\n\u003cp\u003eBut the authors highlight a crucial problem: the \u003cstrong\u003enumber needed to treat was 8:1\u003c\/strong\u003e — meaning 8 patients had to receive suppressive therapy for 1 patient to benefit. Worse, TSH suppression therapy exposed patients to the risks of \u003cstrong\u003ebone loss and cardiac complications\u003c\/strong\u003e from chronic iatrogenic (medically induced) hyperthyroidism. Current American Thyroid Association guidelines now explicitly \u003cstrong\u003erecommend against TSH suppression therapy\u003c\/strong\u003e as a standard treatment for benign nodules in patients with normal thyroid function and sufficient iodine intake.\u003c\/p\u003e\n\n\u003ch2 id=\"surgery\"\u003eSurgical Treatment Options\u003c\/h2\u003e\n\n\u003cp\u003eSurgery for benign thyroid nodules may be considered when there are \u003cstrong\u003ecompression symptoms\u003c\/strong\u003e, such as:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eDifficulty swallowing (dysphagia)\u003c\/li\u003e\n  \u003cli\u003eHoarseness\u003c\/li\u003e\n  \u003cli\u003eA choking sensation\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eCosmetic concerns are also a legitimate reason to consider surgery. Some researchers advocate that nodules larger than \u003cstrong\u003e3–4 cm\u003c\/strong\u003e should be considered for removal, although practical experience suggests that close follow-up of cytologically proven benign, asymptomatic nodules of this size is also a reasonable approach.\u003c\/p\u003e\n\n\u003cp\u003eNodules found to harbor cancer, as well as those with indeterminate cytology or molecular test results indicating a significant cancer risk, typically undergo surgical resection. The \u003cstrong\u003eextent of surgery\u003c\/strong\u003e (lobectomy versus total thyroidectomy) is influenced by several risk factors:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eA history of childhood radiation exposure\u003c\/li\u003e\n  \u003cli\u003eHistology of the tumor (aggressive differentiated thyroid cancer variants, medullary thyroid cancer, or anaplastic thyroid cancer)\u003c\/li\u003e\n  \u003cli\u003eThe presence of bilateral nodules (particularly those larger than 1 cm on the opposite side)\u003c\/li\u003e\n  \u003cli\u003eA family history of thyroid cancer\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eActive surveillance\u003c\/strong\u003e is an option for \u003cstrong\u003emicropapillary thyroid cancers\u003c\/strong\u003e (papillary cancers smaller than 1 cm) that appear to be limited to the thyroid. Ideally, these microcarcinomas should be surrounded by a rim of normal thyroid tissue, and the patient must be willing to undergo close follow-up with serial ultrasound imaging.\u003c\/p\u003e\n\n\u003cp\u003eThe authors strongly recommend that thyroid surgery be performed by \u003cstrong\u003eexperienced, high-volume thyroid surgeons\u003c\/strong\u003e, as this minimizes surgical risks. Those risks include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTransient or permanent \u003cstrong\u003epostoperative hypoparathyroidism\u003c\/strong\u003e (damage to the parathyroid glands, causing low calcium levels)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHoarseness and voice changes\u003c\/strong\u003e from recurrent laryngeal nerve damage\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003ePatients considering surgery should also be counseled about the risk of hypothyroidism after surgery. After \u003cstrong\u003ehemithyroidectomy\u003c\/strong\u003e (removal of half the thyroid), approximately \u003cstrong\u003e15%–50% of patients\u003c\/strong\u003e develop hypothyroidism requiring lifelong thyroid hormone replacement. The risk is higher in patients with a smaller amount of residual thyroid tissue, a higher preoperative TSH level, or underlying chronic lymphocytic thyroiditis (Hashimoto's disease). Of course, \u003cstrong\u003eall patients develop hypothyroidism after total thyroidectomy\u003c\/strong\u003e and will need lifelong thyroid hormone therapy.\u003c\/p\u003e\n\n\u003ch2 id=\"nonsurgical\"\u003eNonsurgical Treatment Options\u003c\/h2\u003e\n\n\u003cp\u003eNonsurgical management of benign thyroid nodules is a growing field, offering patients alternatives to surgery. These minimally invasive approaches include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEthanol ablation\u003c\/strong\u003e — injection of alcohol directly into the nodule, particularly appropriate for treating pure thyroid cysts or autonomous (hyperfunctioning) nodules\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSclerotherapy\u003c\/strong\u003e — a related technique for thyroid cysts\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThermal techniques\u003c\/strong\u003e, including \u003cstrong\u003eradiofrequency ablation\u003c\/strong\u003e, \u003cstrong\u003elaser ablation\u003c\/strong\u003e, \u003cstrong\u003emicrowave ablation\u003c\/strong\u003e, and \u003cstrong\u003ehigh-intensity focused ultrasound (HIFU)\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe authors stress an important safety rule: before any nonsurgical therapeutic option is used, the nodule should be \u003cstrong\u003eproven benign\u003c\/strong\u003e, preferably by \u003cstrong\u003etwo FNAB samples\u003c\/strong\u003e. One sample may suffice in very low-risk nodules. In addition, \u003cstrong\u003eanticoagulation (blood-thinning) therapy should be held\u003c\/strong\u003e before the procedure to reduce bleeding risk.\u003c\/p\u003e\n\n\u003cp\u003eComplications from thermal treatments vary depending on patient selection and operator experience. One notable complication of ethanol ablation is \u003cstrong\u003eintraprocedural perithyroidal ethanol leakage\u003c\/strong\u003e, which can cause significant patient discomfort.\u003c\/p\u003e\n\n\u003cp\u003eThese nonsurgical techniques are particularly valuable for patients who are poor surgical candidates, who wish to avoid general anesthesia and surgery, or who have had prior thyroid surgery and develop recurrent nodules.\u003c\/p\u003e\n\n\u003ch2 id=\"conclusion\"\u003eConclusion: Key Takeaways\u003c\/h2\u003e\n\n\u003cp\u003eThe authors conclude with several clear messages for clinicians and patients alike:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMost thyroid nodules are benign\u003c\/strong\u003e and can be safely monitored without intervention.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe indications for biopsy and the frequency of imaging should be individualized\u003c\/strong\u003e, based on a patient's specific risk stratification rather than a one-size-fits-all approach.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTreatment options should be personalized\u003c\/strong\u003e to each patient's particular situation—there is no single \"best\" approach for everyone.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eActive surveillance should be considered\u003c\/strong\u003e in certain cases of papillary microcarcinoma (papillary thyroid cancers smaller than 1 cm), rather than rushing to surgery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdvances in molecular testing\u003c\/strong\u003e have reduced the number of diagnostic surgeries for asymptomatic nodules with indeterminate cytology.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eEmerging nonsurgical techniques\u003c\/strong\u003e—including ethanol ablation, sclerotherapy, and thermal ablation methods—offer effective alternatives for patients with benign symptomatic nodules.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eAs a narrative review article, this paper has several inherent limitations that patients should understand. First, it is \u003cstrong\u003enot a randomized controlled trial\u003c\/strong\u003e, so it cannot provide definitive comparative data on which treatment strategy is superior; instead, it synthesizes the best available evidence from multiple studies of varying designs and quality. Second, the literature search was limited to the past 5 years, meaning older foundational studies are only included if referenced by more recent papers—though the authors did examine reference lists to capture older key works. Third, the rapid evolution of both imaging technology and molecular testing means that some recommendations may become outdated quickly. Fourth, the authors note areas of genuine controversy, such as the management of subcentimeter nodules and the appropriate role of molecular testing, where expert opinion differs and high-quality outcomes data are still lacking. Finally, the cost-effectiveness considerations mentioned in the article (particularly for molecular tests) are based on U.S. healthcare pricing and may not generalize to other countries.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eIf you have been diagnosed with a thyroid nodule, here are practical steps to consider based on this review:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your TSH levels.\u003c\/strong\u003e A simple blood test determines whether your thyroid function is normal, overactive, or underactive. If your TSH is low, a nuclear thyroid scan may be recommended to see if the nodule is \"hot\" (hyperfunctioning and very unlikely to be cancer).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about your nodule's ultrasound features.\u003c\/strong\u003e Your doctor should be able to tell you whether your nodule falls into a low, intermediate, or high suspicion category. This directly affects whether and when a biopsy is needed. Don't be surprised if nodules smaller than 1 cm are monitored rather than biopsied—this is now standard of care.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf biopsy is recommended, understand what the results mean.\u003c\/strong\u003e The Bethesda category of your FNA result (I–VI) determines the next steps. If you receive an indeterminate result (Bethesda III or IV), ask your doctor whether molecular testing is appropriate. These tests can often clarify whether surgery is necessary.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about active surveillance.\u003c\/strong\u003e If you have a small papillary microcarcinoma, active surveillance with regular ultrasound is a legitimate and increasingly preferred option in appropriate cases—not every cancer requires immediate surgery.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExplore nonsurgical options if surgery is undesirable.\u003c\/strong\u003e If you have a benign nodule that is causing symptoms, techniques like radiofrequency ablation, ethanol ablation, or sclerotherapy may be options. Make sure the nodule has been confirmed benign, ideally by two biopsies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMatch the follow-up plan to your risk, not just nodule size.\u003c\/strong\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is a thyroid nodule and how common are they?\u003c\/h3\u003e\n\u003cp\u003eA thyroid nodule is a growth in the butterfly-shaped thyroid gland. They are common, present in 20% to 60% of adults when healthy volunteers are screened with ultrasound. Most cause no symptoms and are found incidentally. Fewer than 5% of nodules in the general population are cancerous.\u003c\/p\u003e\n\u003ch3\u003eHow do doctors tell if a thyroid nodule is cancer?\u003c\/h3\u003e\n\u003cp\u003eDoctors use ultrasound to assess features like size, shape, margins, and calcifications. Based on risk-stratification systems like TI-RADS or ATA, they decide if a biopsy is needed. No single ultrasound feature is enough to diagnose cancer. A fine-needle aspiration biopsy provides cells for diagnosis.\u003c\/p\u003e\n\u003ch3\u003eWhat is fine-needle aspiration biopsy (FNAB) and when is it recommended?\u003c\/h3\u003e\n\u003cp\u003eFNAB uses a very thin needle under ultrasound guidance to sample cells from a thyroid nodule. It is recommended when ultrasound features and nodule size meet risk-based criteria from systems like TI-RADS or ATA. Nodules smaller than 1 centimeter are often monitored rather than biopsied.\u003c\/p\u003e\n\u003ch3\u003eWhat are the treatment options for a benign thyroid nodule?\u003c\/h3\u003e\n\u003cp\u003eIf a benign nodule causes no symptoms, active monitoring is usually all that is needed. For symptomatic benign nodules, options include surgery or nonsurgical techniques like ethanol ablation, sclerotherapy, or thermal ablation such as radiofrequency or laser. The choice depends on your individual situation.\u003c\/p\u003e\n\u003ch3\u003eWhat is active surveillance for thyroid cancer?\u003c\/h3\u003e\n\u003cp\u003eActive surveillance is a management option for papillary microcarcinomas, which are papillary thyroid cancers smaller than 1 centimeter. It involves close follow-up with serial ultrasounds rather than immediate surgery. This is increasingly preferred in appropriate cases, such as when the tumor appears limited to the thyroid.\u003c\/p\u003e\n\u003ch3\u003eWhy might I need a nuclear thyroid scan if my TSH is low?\u003c\/h3\u003e\n\u003cp\u003eA low TSH level suggests the thyroid may be overactive. In this case, a radioactive iodine uptake test and thyroid scan can determine if a nodule is hyperfunctioning, or 'hot.' Hot nodules are rarely malignant and generally do not require biopsy, so this scan can help avoid an unnecessary procedure.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47427817898140,"sku":null,"price":0.0,"currency_code":"DKK","in_stock":true}],"url":"https:\/\/diagnosticdetectives.dk\/products\/understanding-thyroid-nodules-a-complete-guide-to-diagnosis-and-management","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}